Back to top
more

atai Life Sciences (ATAI)

(Delayed Data from NSDQ)

$1.87 USD

1.87
832,741

-0.10 (-5.08%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $1.87 0.00 (0.00%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ATAI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

atai Life Sciences N.V. [ATAI]

Reports for Purchase

Showing records 1 - 20 ( 59 total )

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 1

01/19/2024

Company Report

Pages: 8

Emerging Neuro Leader Poised to Shine; Multiple Phase 2 Readouts Expected in 2024 and 2025; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 2

01/04/2024

Daily Note

Pages: 4

Transformational Beckley Collaboration to Drive Leadership in Psychedelics in Psychiatry; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 3

01/02/2024

Daily Note

Pages: 3

EMP-01 Generates Promising Phase 1 Data in Next Generation Psychedelic Program Addressing PTSD; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 4

11/16/2023

Company Report

Pages: 8

3Q23 Results; Early Stage Data Emerging; RL-007 Phase 2a Data Expected 2H24; Unveils New Psychedelics; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 5

10/05/2023

Company Report

Pages: 7

Novel Formulation of DMT Clears Another Hurdle; Plans Phase 1b in 1H24 Before Moving to Phase 2; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 6

09/19/2023

Industry Report

Pages: 14

Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 7

08/14/2023

Company Report

Pages: 9

2Q23 Results; Early Stage Psychedelic Compounds Advancing; RL-007 in CIAS on Track for Phase 2 Data in 2H24; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 8

07/10/2023

Company Report

Pages: 9

Lead Compounds VLS-01 in Depression and GRX-917 in Anxiety on Track; Multiple Catalysts Expected in 2H23; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 9

06/15/2023

Company Report

Pages: 10

1Q23 Results; Multiple Psychedelic Data Readouts Expected in 2023; Non-Psychedelic Programs Advancing on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 10

03/28/2023

Company Report

Pages: 10

4Q22 Results; Multiple Psychoactive Agents to Generate Early Stage Data in 2023; Non-Psychedelic Pipeline Progressing

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 11

01/26/2023

Industry Report

Pages: 10

Bullish Start to the Year for Psychedelic Drug Development Companies Ahead of a Plethora of Potential Positive Events

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 12

01/19/2023

Company Report

Pages: 10

Remains Focused on Advancing Broad Pipeline Following Recent Setbacks; Lowering Price Target to $20; Maintain Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 13

01/06/2023

Daily Note

Pages: 4

Following Mixed Phase 2a Dataset From PCN-101, Focus in Depression to Shift to Short-Acting Psychedelic DMT

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 14

12/02/2022

Industry Report

Pages: 5

Biotechnology Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 15

11/18/2022

Company Report

Pages: 10

3Q22 Results; PCN-101 Phase 2a Trial Top-Line Data Expected in 4Q; Broad Pipeline Progressing on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 16

11/10/2022

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 17

11/10/2022

Company Report

Pages: 5

3Q22 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 5.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 18

10/28/2022

Company Report

Pages: 13

R&D Day Highlights Broad Pipeline Progress; Psychedelic Programs Advancing in Depression and Addiction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 19

10/26/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: atai Life Sciences N.V.

Industry: Medical - Outpatient and Home Healthcare

Record: 20

10/25/2022

Company Report

Pages: 5

R&D Day Takeaways

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 5.00

Research Provided by a Third Party